177 related articles for article (PubMed ID: 35312176)
1. Relationship between perioperative oncological evaluation and recurrence using circulating tumor DNA with KRAS mutation in patients with colorectal cancer.
Hayashi T; Yoshida Y; Yamada T; Tanaka K; Shimaoka H; Kajitani R; Munechika T; Nagano H; Matsumoto Y; Komono A; Sakamoto R; Aisu N; Yoshimatsu G; Yoshimura F; Hasegawa S
Cancer Med; 2022 Aug; 11(16):3126-3135. PubMed ID: 35312176
[TBL] [Abstract][Full Text] [Related]
2. Preoperative detection of KRAS mutated circulating tumor DNA is an independent risk factor for recurrence in colorectal cancer.
Nakamura Y; Yokoyama S; Matsuda K; Tamura K; Mitani Y; Iwamoto H; Mizumoto Y; Murakami D; Kitahata Y; Yamaue H
Sci Rep; 2021 Jan; 11(1):441. PubMed ID: 33432066
[TBL] [Abstract][Full Text] [Related]
3. A Novel Multiplex Droplet Digital PCR Assay to Identify and Quantify KRAS Mutations in Clinical Specimens.
Alcaide M; Cheung M; Bushell K; Arthur SE; Wong HL; Karasinska J; Renouf D; Schaeffer DF; McNamara S; Tertre MCD; Batist G; Kennecke HF; Karsan A; Morin RD
J Mol Diagn; 2019 Mar; 21(2):214-227. PubMed ID: 30472330
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and patterns of mutations in RAS/RAF/MEK/ERK/MAPK signaling pathway in colorectal cancer in North Africa.
Jafari M; Laraqui A; Baba W; Benmokhtar S; Zaitouni SE; Ali AA; Bounaim A; Moujahid M; Tanz R; Mahfoud T; Sbitti Y; Annaz HE; Abi R; Tagajdid MR; Kochri SE; Lahlou IA; Hsaini HE; Belayachi L; Benjouad A; Ichou M; En-Nya A; Ennibi K
BMC Cancer; 2022 Nov; 22(1):1142. PubMed ID: 36344948
[TBL] [Abstract][Full Text] [Related]
5. Detection of KRAS mutations in liquid biopsies from metastatic colorectal cancer patients using droplet digital PCR, Idylla, and next generation sequencing.
Holm M; Andersson E; Osterlund E; Ovissi A; Soveri LM; Anttonen AK; Kytölä S; Aittomäki K; Osterlund P; Ristimäki A
PLoS One; 2020; 15(11):e0239819. PubMed ID: 33237900
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of specific KRAS mutations in patients with colorectal peritoneal metastases.
Tonello M; Baratti D; Sammartino P; Di Giorgio A; Robella M; Sassaroli C; Framarini M; Valle M; Macrì A; Graziosi L; Coccolini F; Lippolis PV; Gelmini R; Deraco M; Biacchi D; Aulicino M; Vaira M; De Franciscis S; D'Acapito F; Carboni F; Milone E; Donini A; Fugazzola P; Faviana P; Sorrentino L; Pizzolato E; Cenzi C; Del Bianco P; Sommariva A
ESMO Open; 2024 Apr; 9(4):102976. PubMed ID: 38613907
[TBL] [Abstract][Full Text] [Related]
7. Detection of KRAS Mutations in Circulating Tumor DNA by Digital PCR in Early Stages of Pancreatic Cancer.
Brychta N; Krahn T; von Ahsen O
Clin Chem; 2016 Nov; 62(11):1482-1491. PubMed ID: 27591291
[TBL] [Abstract][Full Text] [Related]
8. Oncological evaluation in the perioperative period using cfDNA with BRAF V600E mutation in patients with colorectal cancer.
Tanaka K; Yoshida Y; Yamada T; Hayashi T; Shimaoka H; Yoshimura F; Kajitani R; Munechika T; Matsumoto Y; Nagano H; Komono A; Sakamoto R; Nakashima R; Aisu N; Yoshimatsu G; Hasegawa S
Sci Rep; 2021 Jun; 11(1):13263. PubMed ID: 34168268
[TBL] [Abstract][Full Text] [Related]
9. Metabolic characterization of colorectal cancer cells harbouring different KRAS mutations in codon 12, 13, 61 and 146 using human SW48 isogenic cell lines.
Varshavi D; Varshavi D; McCarthy N; Veselkov K; Keun HC; Everett JR
Metabolomics; 2020 Apr; 16(4):51. PubMed ID: 32300895
[TBL] [Abstract][Full Text] [Related]
10. Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial.
Bidard FC; Kiavue N; Ychou M; Cabel L; Stern MH; Madic J; Saliou A; Rampanou A; Decraene C; Bouché O; Rivoire M; Ghiringhelli F; Francois E; Guimbaud R; Mineur L; Khemissa-Akouz F; Mazard T; Moussata D; Proudhon C; Pierga JY; Stanbury T; Thézenas S; Mariani P
Cells; 2019 May; 8(6):. PubMed ID: 31142037
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic Strategies toward Clinical Implementation of Liquid Biopsy RAS/BRAF Circulating Tumor DNA Analyses in Patients with Metastatic Colorectal Cancer.
van 't Erve I; Greuter MJE; Bolhuis K; Vessies DCL; Leal A; Vink GR; van den Broek D; Velculescu VE; Punt CJA; Meijer GA; Coupé VMH; Fijneman RJA
J Mol Diagn; 2020 Dec; 22(12):1430-1437. PubMed ID: 32961317
[TBL] [Abstract][Full Text] [Related]
12. Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer.
Lee MR; Woo SM; Kim MK; Han SS; Park SJ; Lee WJ; Lee DE; Choi SI; Choi W; Yoon KA; Chun JW; Kim YH; Kong SY
Cancer Sci; 2024 Apr; 115(4):1283-1295. PubMed ID: 38348576
[TBL] [Abstract][Full Text] [Related]
13. The potential of PIK3CA, KRAS, BRAF, and APC hotspot mutations as a non-invasive detection method for colorectal cancer.
Alizadeh-Sedigh M; Mahmoodzadeh H; Fazeli MS; Haddadi-Aghdam M; Teimoori-Toolabi L
Mol Cell Probes; 2022 Jun; 63():101807. PubMed ID: 35296442
[TBL] [Abstract][Full Text] [Related]
14. Detection of tumor-derived cell-free DNA from colorectal cancer peritoneal metastases in plasma and peritoneal fluid.
Van't Erve I; Rovers KP; Constantinides A; Bolhuis K; Wassenaar EC; Lurvink RJ; Huysentruyt CJ; Snaebjornsson P; Boerma D; van den Broek D; Buffart TE; Lahaye MJ; Aalbers AG; Kok NF; Meijer GA; Punt CJ; Kranenburg O; de Hingh IH; Fijneman RJ
J Pathol Clin Res; 2021 May; 7(3):203-208. PubMed ID: 33635598
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.
Watanabe F; Suzuki K; Tamaki S; Abe I; Endo Y; Takayama Y; Ishikawa H; Kakizawa N; Saito M; Futsuhara K; Noda H; Konishi F; Rikiyama T
PLoS One; 2019; 14(12):e0227366. PubMed ID: 31891652
[TBL] [Abstract][Full Text] [Related]
16. Detection of KRAS mutations in circulating tumour DNA from plasma and urine of patients with colorectal cancer.
Ohta R; Yamada T; Sonoda H; Matsuda A; Shinji S; Takahashi G; Iwai T; Takeda K; Ueda K; Kuriyama S; Miyasaka T; Yokoyama Y; Hara K; Yoshida H
Eur J Surg Oncol; 2021 Dec; 47(12):3151-3156. PubMed ID: 34315643
[TBL] [Abstract][Full Text] [Related]
17. Serial Circulating Tumor DNA Mutational Status in Patients with KRAS-Mutant Metastatic Colorectal Cancer from the Phase 3 AIO KRK0207 Trial.
Lueong SS; Herbst A; Liffers ST; Bielefeld N; Horn PA; Tannapfel A; Reinacher-Schick A; Hinke A; Hegewisch-Becker S; Kolligs FT; Siveke JT
Clin Chem; 2020 Dec; 66(12):1510-1520. PubMed ID: 33257977
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the Clinical Sensitivity of the Idylla Platform and the OncoBEAM RAS CRC Assay for KRAS Mutation Detection in Liquid Biopsy Samples.
Vivancos A; Aranda E; Benavides M; Élez E; Gómez-España MA; Toledano M; Alvarez M; Parrado MRC; García-Barberán V; Diaz-Rubio E
Sci Rep; 2019 Jun; 9(1):8976. PubMed ID: 31222012
[TBL] [Abstract][Full Text] [Related]
19. Detection of mutations in circulating cell-free DNA in relation to disease stage in colorectal cancer.
Liebs S; Keilholz U; Kehler I; Schweiger C; Haybäck J; Nonnenmacher A
Cancer Med; 2019 Jul; 8(8):3761-3769. PubMed ID: 31134762
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Circulating Tumor DNA in Patients with Ovarian Cancer Harboring Somatic PIK3CA or KRAS Mutations.
Ogasawara A; Hihara T; Shintani D; Yabuno A; Ikeda Y; Tai K; Fujiwara K; Watanabe K; Hasegawa K
Cancer Res Treat; 2020 Oct; 52(4):1219-1228. PubMed ID: 32599986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]